Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RAY1225
- Development stage
- Phase 3
- Lead developer
- Raynovent Biotech
- Modality
- Peptides
- Administration
- Subcutaneous
01
Overview
RAY1225 is a synthetic peptide drug that acts as a dual agonist of the glucagon-like peptide 1 receptor (GLP-1R) and gastric inhibitory polypeptide receptor (GIPR). It is being developed primarily for the treatment of obesity, type 2 diabetes mellitus, and nonalcoholic steatohepatitis. The drug mimics incretin hormones to enhance insulin secretion, suppress appetite, reduce body weight, and improve glycemic control. Developed by Guangdong Raynovent Biotech (a subsidiary of Guangdong Zhongsheng Pharma), it has reached Phase 3 clinical trials for obesity and overweight indications. Clinical studies have demonstrated significant efficacy in weight loss and blood glucose control compared to placebo[2][3][10].
- Other names
- 14C-RAY1225
02
Targets
GIPR (Gastric inhibitory polypeptide receptor)GLP1R (GLP-1R)
Beyond the preview
Go deeper on RAY1225.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RAY1225.